Maple Grove is getting a very 21st-century kind of factory: one where microbes, corn sugar, and fermentation could help produce plastics, chemicals, aviation materials, and even cement. The ambitious project is designed to tackle a stubborn problem in American manufacturing — plenty of promising biotechnology gets developed in U.S. labs, but not enough of it gets scaled into domestic production.
That is the central pitch behind a Wednesday conversation with BioMADE Chief Operating Officer Jill Zullo, whose career includes nearly three decades at Cargill and a stint as CEO of NatureWorks. In the Twin Cities Business interview, Zullo described how engineered microbes can convert agricultural feedstocks into useful industrial materials — essentially putting biology to work on the factory floor.
Why Maple Grove Is BioMADE’s Big Test
BioMADE’s planned Maple Grove facility represents at least $132 million in investment and will occupy a 122,000-square-foot site with large-scale fermentation and downstream processing equipment. BioMADE said the site will give companies access to demonstration-scale tools, including 25,000-liter industrial fermenters, so they can test whether a lab process can survive the messy, expensive jump to commercial production.
That missing middle is where many biotech ideas go to die. The Star Tribune reported that Minnesota is contributing $50 million toward the Maple Grove project, with the Department of Defense covering the rest, as BioMADE tries to build shared infrastructure that individual companies may not be able to justify on their own.
From Corn Sugar To Defense Materials
The potential products are broader than the usual conversation about biodegradable packaging. BioMADE’s facility is expected to support work involving coatings, adhesives, lubricants, lightweight composites, thermal-protection materials, plant-based fabrics, detergents, personal-care products, and bioplastics — a mix that explains why the project has both commercial and national-security appeal.
The organization’s broader pipeline is moving in the same direction. In an April project announcement, BioMADE said it was putting more than $21 million into 14 projects involving products such as lithium-recovery systems, 3D-printing plastics, biosensors, advanced proteins, and new fermentation technologies, while also funding apprenticeships and other workforce programs.
The Supply-Chain Pitch Is Finding An Audience
The timing is notable because BioMADE released a new national survey this month arguing that Americans are increasingly receptive to the idea of government-backed domestic biomanufacturing. According to the group’s survey release, 56% of respondents wanted more American-made bio-based products in stores and supply chains, while six in 10 supported federal investment in biomanufacturing research and production.
For Minnesota, the wager is that agricultural feedstocks, research institutions, manufacturing know-how, and a growing biotechnology workforce can be assembled in one regional ecosystem. Maple Grove’s facility is not a consumer-products factory yet; it is the expensive proving ground where a startup, a major manufacturer, or a defense contractor can find out whether its science is ready for the real world.
If BioMADE’s plan works, the payoff will not be limited to a few new products with a “made from plants” label. The larger goal is to keep intellectual property, production expertise, and eventually more manufacturing jobs in the United States — with Maple Grove serving as one of the places where corn and microbes are asked to carry an unusually large economic load.
